CatalyScope is a clinical intelligence publisher focused on Phase 3 development programs within small- and mid-cap pharmaceutical and biotechnology companies (market capitalisation below $10 billion USD). Our platform systematically tracks upcoming primary endpoint readouts using publicly available clinical trial registry data.

Through our Hidden Helix pipeline — which integrates structured data from global clinical trial databases with AI-assisted summarisation — CatalyScope identifies when key trial milestones are scheduled to occur and presents trial design, sponsor information, patient enrollment, therapeutic context, historical phase transition data, and competitive landscape information in a structured research format.

In addition to the searchable database below, CatalyScope publishes a detailed monthly report outlining the following month’s upcoming Phase 3 primary endpoint readouts within our coverage universe. The report provides structured summaries and contextual information intended to support independent research.

You can access the latest monthly publication here: View Monthly Catalyst Report.

CatalyScope provides informational and educational research only. Nothing on this website constitutes investment advice, a recommendation, or an offer to buy or sell any security.

Hidden Helix runs automatically once a week — last run on Mar 2, 2026. Trials are included up to one year prior to the run date. The results from the most recent update are displayed below.